![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Prof. Burkhard Becher
becher@immunology.uzh.ch
41-446-353-703
University of Zurich
Caption: Deficiency (or inhibition) of molecules of the interleukin (IL)-12 and/or IL-23 signal pathway reduces Alzheimer-like pathological changes – depicted here as so-called β-amyloid plaques (spot-like areas, stained in black) – substantially. Left: Brain hemisphere of an Alzheimer’s mouse; right: Brain hemisphere of an Alzheimer’s mouse without IL-12 receptor.
Credit: UZH
Usage Restrictions: None
Related news release: Alzheimer's disease in mice alleviated promising therapeutic approach for humans
|